表紙
市場調查報告書

圍繞癌症免疫診斷市場預測及分析:生物標記的相爭

Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024

出版商 Howe Sound Research 商品編碼 804234
出版日期 內容資訊 英文 277 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
圍繞癌症免疫診斷市場預測及分析:生物標記的相爭 Immuno-Oncology Diagnostics, The Race for Biomarkers, Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis 2020 to 2024
出版日期: 2019年11月02日內容資訊: 英文 277 Pages
簡介

本報告提供全球癌症免疫診斷市場相關調查,免疫療法的技術指南,產業概要,市場成長的影響要素,技術開發趨勢,近幾年的發展趨勢,世界市場規模,各類型的市場,及主要企業等相關分析。

第1章 簡介、市場定義

第2章 免疫療法:對免疫技術的指南

  • 免疫系統
    • 先天性免疫系統
    • 適應免疫系統
    • 腫瘤免疫學
  • 癌症免疫診斷
    • 查核點化驗
    • 細胞激素化驗
    • 生殖細胞系列基因
    • 癌症基因
    • 腫瘤微環境
    • 其他

第3章 產業概要

  • 動態市場上企業/研究所等

第4章 市場趨勢

  • 推動成長要素
  • 成長的阻礙因素
  • 診斷技術的開發

第5章 癌症免疫療法的近幾年的發展趨勢

  • 近幾年的發展:重要性、利用法

第6章 主要免疫療法企業的簡介

  • 10X Genomics
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • bioMerieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

第7章 世界市場規模

  • 癌症免疫診斷的全球市場規模:各國,附圖表
  • 癌症免疫診斷的全球市場規模:各類型,附圖表

第8章 全球市場:各類型

  • 查核點化驗市場
  • 細胞激素化驗市場
  • 生殖細胞系列基因市場
  • 癌症基因市場
  • 腫瘤微環境市場
  • 其他市場

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants
  • iD. Impact of the Nobel Prize

1. Introduction and Market Definition

  • 1.1 What are Immuno-Oncology Diagnostics?
  • 1.2 Immuno-oncology - the looming cure
    • 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 1.3 Market Definition
    • 1.3.1 Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies

  • 2.0 The Immune System
    • 2.0.1 Innate immune system
      • 2.0.1.1 Surface barriers
      • 2.0.1.2 Inflammation
      • 2.0.1.3 Complement system
      • 2.0.1.4 Cellular barriers
      • 2.0.1.5 Natural killer cells
    • 2.0.2 Adaptive immune system
      • 2.0.2.1 Lymphocytes
      • 2.0.2.2 Killer T cells
      • 2.0.2.3 Helper T cells
      • 2.0.2.4 Gamma delta T cells
      • 2.0.2.5 B lymphocytes and antibodies
    • 2.0.3 Tumor immunology - the immune surveillance system
  • 2.1 Immuno OncologyDiagnostics
    • 2.1.1 Checkpoint Assays
      • 2.1.1.1 Outlook for Checkpoint Assays
    • 2.1.2 Cytokine Assays
      • 2.1.2.1 Outlook for Cytokine Assays
    • 2.1.3 Genomic Germline
      • 2.1.3.1 Outlook for Genomic Germline
    • 2.1.4 Genomic Tumour
      • 2.1.4.1 Outlook for Genomic Tumour
    • 2.1.5 Tumor Microenviroment
      • 2.1.5.1 Outlook for Tumor Micro Environment
    • 2.1.6 Others
      • 2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Genomic Instrumentation Supplier
  • 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4 Pharmaceutical/Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Outcome potential
    • 4.1.2 Companion Diagnostics
    • 4.1.3 Funding
    • 4.1.4 Technology Environment
    • 4.1.5 Target Solutions
  • 4.2 Factors Limiting Growth
    • 4.2.1 Complex Role of Diagnostics
    • 4.2.2 Clinical Trials Role
    • 4.2.3 Protocols
  • 4.3 Diagnostic Technology Development
    • 4.3.1 Combinations - Issues and Complexity
    • 4.3.2 Shifting Role of Diagnostics
    • 4.3.3 Multiplexing and Foundation One
    • 4.3.4 The Disruption Dynamic
    • 4.3.5 The Race for Biomarkers
    • 4.3.6 The Next Five Years

5. Cancer Immunotherapy Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
      • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
      • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
      • Generex to Merge with NuGenerex Immuno-Oncology
      • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
      • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer
      • Icon Acquires MolecularMD
      • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
      • Tumor Mutational Burden as Predictor of Immunotherapy Success
      • Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
      • Abcam Acquires Calico Biolabs
      • Cancer Genetics and NovellusDx to Merge
      • ApoCell Expands Immuno-Oncology Biomarker Services
      • MRM Proteomics Inc and Exactis Innovation Partner
      • Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
      • Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
      • MolecularMD Launches Validated Tumor Mutation Burden Assay
      • Minomic Secures Key Patent in the United States and China
      • Biocartis and Wondfo Announce Joint Venture
      • Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
      • Cancer Genetics Expands Immuno-Oncology Panel
      • 10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product
      • Qiagen, Freenome Partner to Improve Companion Diagnostic Development
      • Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime
      • Thermo Fisher Expands Oncomine Immuno-Oncology Assay Portfolio
      • Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies
      • HalioDx announces high capacity IHC multiplex technology
      • MolecularMD to Implement Promega's Technology
      • NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel
      • MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response
      • Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC
      • HalioDx Closes €18.5M Series B Round
      • Announcement of the 2018 Nobel Prize in Physiology or Medicine

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMérieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. Global Market Size

  • 7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts
  • 7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts

8. Global Market by Type

  • 8.1 Checkpoint Assay Market
    • 8.1.1 Checkpoint Assay Market by Country with Chart
  • 8.2 Cytokine Assay Market
    • 8.2.1 Cytokine Assay Market by Country with Chart
  • 8.3 Genome Germline Market
    • 8.3.1 Genome Germline Market by Country with Chart
  • 8.4 Genome Tumour Market
    • 8.4.1 Genome Tumour Market by Country with Chart
  • 8.5 Tumour Micro Environment Market
    • 8.5.1 Tumour Micro Environment Market by Country with Chart
  • 8.6 Other Market
    • 8.6.1 Other Market by Country with Chart

9. Appendices

  • 9.1 FDA Cancer Drug Approvals by Year
  • 9.2 Clinical Trials Started 2010 to 2016
  • 9.3 Prevalence of Cancer Treatments - 2015

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Overview of Innate and Adaptive Immunity
  • Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 5 FDA Approved Companion diagnostics in Cancer treatment
  • Table 6 Market Players by Type
  • Table 7 Five Factors Driving Growth
  • Table 8 Three Factors Limiting Growth
  • Table 9 Immuno-oncology Diagnostics Global Market by Country/Region
  • Table 10 Immuno-oncology Diagnostics Global Market by Type
  • Table 11 Checkpoint Assay Market by Country
  • Table 12 Cytokine Assay Market by Country
  • Table 13 Genome Germline Market by Country
  • Table 14 Genome Tumour Market by Country
  • Table 15 Tumour Micro Environment Market by Country
  • Table 16 Other Market by Country

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Helper T Cell Roles
  • Figure 4 Antibody Diagram
  • Figure 5 Macrophages attack a Cancer Cell
  • Figure 6 The Tumour Micro Environment
  • Figure 7 Comparing IO Diagnostic and Traditional Testing
  • Figure 8 Growth rates of IO DiagnosticTechnologies
  • Figure 9 Market Size by Country - Key Countries
  • Figure 10 Chart of Global Market by Assay Type Share
  • Figure 11 Growth Rates of Diagnostic Segments
  • Figure 12 IO Diagnostics Share Change by Type
  • Figure 13 Chart - Checkpoint Assay Market vs Total
  • Figure 14 Chart - Cytokine Assay Market vs Total
  • Figure 15 Chart - Genome Germline Market vs Total
  • Figure 16 Chart - Genome Tumour Market vs Total
  • Figure 17 Chart - Tumour Micro Environment Market vs Total
  • Figure 18 Chart - Other Market vs Total
  • Figure 19 FDA Cancer Drug Approvals by Year
  • Figure 20 Clinical Trials for Immunotherapy by Year
  • Figure 21 Pie Chart of Prevalence of Cancer Treatments
Back to Top